MENARINI Group’s Post

Interesting study summarized in Medscape from on a poster presented at the European Society of Clinical Microbiology and Infectious Diseases Global Congress: "Hospital-acquired infections associated with antimicrobial resistance (AMR) increased during the COVID-19 pandemic by 32% and remain 13% higher post pandemic compared with prepandemic levels" #infectionprevention #infectioncontrol #healthcare #patientsafety #AMR APIC https://lnkd.in/evcsiGQ3

𝗗𝗭𝗜𝗙 𝗺𝗮𝗸𝗲𝘀 𝗿𝗲𝘀𝗶𝘀𝘁𝗮𝗻𝘁 𝗯𝗮𝗰𝘁𝗲𝗿𝗶𝗮𝗹 𝘀𝘁𝗿𝗮𝗶𝗻𝘀 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗪𝗛𝗢 𝗽𝗮𝘁𝗵𝗼𝗴𝗲𝗻 𝗹𝗶𝘀𝘁 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 𝗳𝗼𝗿 𝗶𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗮𝗻𝘁𝗶𝗯𝗶𝗼𝘁𝗶𝗰𝘀 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 According to estimates, 4.95 million deaths worldwide in 2019 were directly or indirectly attributable to infections with #resistant bacteria. The rising number of resistant bacterial pathogens, also known as the "creeping pandemic", is increasingly limiting treatment options for infected people and, according to the World Health Organization (WHO), poses the greatest global threat to humanity. In order to focus research and development of new antimicrobial agents on the groups of bacteria for which new #antibiotics are most urgently needed, the WHO has drawn up a prioritised list of #pathogens, which was only recently updated (May 2024). Seventeen bacterial strains from this list have now been made available for research from the collections of the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures (DSMZ)—in particular from the pathogenrepository of the German Center for Infection Research (DZIF). https://lnkd.in/e8WrvfBA Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH Deutsche Zentren der Gesundheitsforschung #AMR #AntimicrobialResistance

#Antibiotic resistance is an escalating global health crisis that could result in the deaths of 39 million people by 2050, according to a comprehensive study. This represents a significant increase from the current rate of approximately 1 million deaths annually due to antibiotic-resistant infections since 1990. The study indicates that the most pronounced rise in mortality is expected among adults aged 70 and older, with an increase exceeding 80%.📈⚠️ To address this critical issue, experts recommend several key strategies. Enhancements in infection prevention and control measures, including the development of new vaccines and improved access to water, sanitation and hygiene, are essential for reducing the spread of resistant pathogens. Additionally, antimicrobial stewardship—defined as the responsible use of antibiotics in humans, animals and agriculture—is vital. This approach emphasizes prescribing antibiotics only when necessary and for the appropriate duration.💊🏥 Early screening and #diagnosis are also crucial in mitigating this crisis. Timely identification of the specific pathogen responsible for an infection enables #healthcare providers to prescribe the most effective antibiotic, rather than resorting to broad-spectrum treatments that may exacerbate resistance. Diagnostic tools capable of rapidly distinguishing between bacterial and viral infections are particularly beneficial, as they help minimize the overuse of antibiotics for viral illnesses. Hangzhou AllTest Biotech Co.,Ltd. is actively innovating and developing products to support efforts in reducing antibiotic misuse and protecting public #health. https://lnkd.in/gCw8wvkt #AntibioticResistance #GlobalHealth #PublicHealth #InfectionControl #Healthcare #Screening #Diagnosis #MedicalInnovation #Antibiotics #AllTest

Learn more about antimicrobial peptides >> #peptides #drugdiscovery

𝐈𝐧 𝐭𝐡𝐞 𝐟𝐚𝐜𝐞 𝐨𝐟 𝐫𝐢𝐬𝐢𝐧𝐠 𝐚𝐧𝐭𝐢𝐛𝐢𝐨𝐭𝐢𝐜 𝐫𝐞𝐬𝐢𝐬𝐭𝐚𝐧𝐜𝐞, 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡𝐞𝐫𝐬 𝐚𝐫𝐞 𝐜𝐨𝐦𝐩𝐞𝐥𝐥𝐞𝐝 𝐭𝐨 𝐞𝐱𝐩𝐥𝐨𝐫𝐞 𝐚𝐥𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐯𝐞 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 𝐭𝐨 𝐜𝐨𝐦𝐛𝐚𝐭 𝐦𝐢𝐜𝐫𝐨𝐛𝐢𝐚𝐥 𝐢𝐧𝐟𝐞𝐜𝐭𝐢𝐨𝐧 - 𝐞𝐧𝐭𝐞𝐫 𝐀𝐧𝐭𝐢𝐦𝐢𝐜𝐫𝐨𝐛𝐢𝐚𝐥 𝐏𝐞𝐩𝐭𝐢𝐝𝐞𝐬 (𝐀𝐌𝐏𝐬). Antibiotics have been pivotal in this battle, known for their specific targeting of bacterial infections, low cost and oral bioavailability. Yet, they face critical challenges like antibiotic resistance and side effects due to low specificity. Peptides, on the other hand, provide some unique advantages and challenges. AMPs are short chains of amino acids inherent to our innate immunity, with a unique mechanism of action that disrupts the cell membranes of pathogens. This means they are effective against various pathogens, including bacteria and viruses, and reduces the likelihood of pathogens developing resistance. AMPs also have potential applications in various medical fields beyond infection control. However, their development has been hindered by issues such as stability and degradation, cost of development and selective toxicity. AI is opening up new doors to overcome some of these traditional challenges and paving the way for peptides as a viable alternative to antibiotics in the fight against infectious diseases. Learn more about AI-driven AMP design >> https://lnkd.in/dWFrGRu6 #Peptides #Antibiotics #DrugDiscovery #AI

A phage bank, a strategic repository of bacteriophages, leverages the specificity and adaptability of these viruses to combat bacterial infections, especially those resistant to conventional antibiotics. This crucial resource offers a diverse array of phages tailored to target specific bacterial pathogens, contributing significantly to phage therapy research and clinical applications. Bacteriophages, as natural predators of bacteria, play a vital role in infection control by infecting and replicating within bacterial cells, leading to their lysis and death. Their high specificity allows for targeted treatment with minimal disruption to the body's microbiota, potentially reducing side effects associated with antibiotic therapies. Collected from various sources like sewage, soil, water bodies, and human or animal microbiomes, phages in these banks undergo rigorous testing to ensure efficacy against target bacterial strains, considering factors like host range, lytic activity, stability, and safety profiles. Phage banks serve critical purposes in treating antibiotic-resistant infections, research and development, and emergency preparedness, addressing challenges in isolation, characterization, storage, and regulatory compliance. By harnessing the evolutionary potential of bacteriophages, these repositories offer a forward-thinking approach to combat antibiotic resistance and revolutionize infectious disease treatment in the future of healthcare. #PhageBank #AntibioticResistance #InfectiousDisease #HealthcareFuture

Antibiotic resistance in pathogenic microorganisms is rapidly increasing worldwide, highlighting the urgent need for novel agents and innovative solutions to treat bacterial infections. Bacteriophages (phages) have emerged as a highly promising alternative to antibiotics due to their ability to specifically infect and inactive bacteria. This specificity is a significant advantage in potential medical applications, as it avoids the broad killing of commensal human bacteria. However, the infection mechanism of phages remains poorly characterized, hindering the development of phage-derived solutions. This is mainly due to a lack of suitable analytical methods for understanding the process on a quantitative, molecular level.  Tail spike proteins (TSPs) are specialized hydrolytic phage proteins located at the end of the phage tail, playing a crucial role in the initial steps of bacterial infection. These proteins bind to the bacterial surface and degrade the bacterial polysaccharide layer, but their exact mechanism is still not fully understood.  

Antimicrobial resistance (AMR) is a major global health threat that occurs when microbes develop resistance to the drugs used to treat them, rendering these drugs ineffective. This can lead to prolonged illnesses, increased risk of spread of infections, and even death. AMR affects a wide range of diseases, including bacterial infections, tuberculosis, malaria, and HIV. One of the biggest challenges of AMR is the overuse and misuse of antibiotics. This can happen through inappropriate prescription practices, use of antibiotics in agriculture, and lack of proper infection prevention and control measures. Additionally, poor access to healthcare in some countries can contribute to the spread of resistant bacteria. The dangers of AMR are vast and can have severe consequences for public health. Without effective antibiotics, common infections such as urinary tract infections, pneumonia, and sepsis could become untreatable. This can lead to increased healthcare costs, longer hospital stays, and higher mortality rates. Possible solutions to address AMR include implementing antibiotic stewardship programs to ensure appropriate use of antibiotics, promoting better hygiene practices in healthcare settings, investing in research and development of new antibiotics, and improving surveillance systems to track resistant bacteria. The World Health Organization (WHO) has identified a list of bacterial pathogens that pose the greatest threat to public health due to their resistance to multiple antibiotics. This list, known as the Priority Pathogens List, includes bacteria such as Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae (including Klebsiella, Escherichia coli, and others). These pathogens are considered a priority for research and development of new antibiotics to combat the growing threat of AMR. #antibiotics #amr #bacteria #onehealth

Professor Joseph Tucci is researching new ways to treat antibiotic resistant bacterial infections.   “We’re losing capacity to treat many bacterial infections," he explains. "A contributing factor is that there aren’t many new antibiotics developed for use. Another crucial issue is that bacteria are becoming more resistant to antibiotics, which means that our usual treatments for infections are less effective.”   Bacteriophages, a type of virus that naturally kill bacteria, are proving a useful weapon in the fight against antimicrobial resistance.   “While antibiotics are effective in killing their intended bacterial targets, they also kill other bacteria in our microbiome. Bacteriophages, on the other hand, offer precision therapy and kill only their target bacteria. They have also evolved with bacteria over billions of years and can kill virulent bacterial strains resistant to antibiotics,” Professor Tucci explains.   In a world-first, Professor Tucci’s team were able to isolate and characterise a lytic bacteriophage against Fusobacterium nucleatum, which worsens outcomes in periodontitis and cancers.   “This means we may be able to assist in the treatment of periodontitis, diabetic ulcers and some cancers, reducing the significant morbidity and mortality caused by these chronic diseases.”   Read more: https://bit.ly/3OSvlnL   #LaTrobeRuralHealthSchool #AntibioticResistance

𝗧𝗵𝗲 𝗪𝗼𝗿𝗹𝗱 𝗛𝗲𝗮𝗹𝘁𝗵 𝗢𝗿𝗴𝗮𝗻𝗶𝘇𝗮𝘁𝗶𝗼𝗻 (𝗪𝗛𝗢) 𝗵𝗮𝘀 𝗱𝗲𝗰𝗹𝗮𝗿𝗲𝗱 𝘁𝗵𝗲 𝗺𝗽𝗼𝘅 (𝗠𝗣𝗫𝗩) 𝗼𝘂𝘁𝗯𝗿𝗲𝗮𝗸𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗗𝗲𝗺𝗼𝗰𝗿𝗮𝘁𝗶𝗰 𝗥𝗲𝗽𝘂𝗯𝗹𝗶𝗰 𝗼𝗳 𝘁𝗵𝗲 𝗖𝗼𝗻𝗴𝗼 (𝗗𝗥𝗖) 𝗮𝗻𝗱 𝗼𝘁𝗵𝗲𝗿 𝗔𝗳𝗿𝗶𝗰𝗮𝗻 𝗰𝗼𝘂𝗻𝘁𝗿𝗶𝗲𝘀 𝗮 𝗽𝘂𝗯𝗹𝗶𝗰 𝗵𝗲𝗮𝗹𝘁𝗵 𝗲𝗺𝗲𝗿𝗴𝗲𝗻𝗰𝘆 𝗼𝗳 𝗶𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗰𝗼𝗻𝗰𝗲𝗿𝗻 (𝟭). For mpox sample collection, inactivation and transport, E&O Laboratories produces Molecular Sampling Solution (MSS), a reagent formulated and validated for the inactivation and transportation of specimens potentially containing a wide range of viral and bacterial pathogens, including mpox. MSS is designed to disrupt microorganisms, denature proteins and nucleases and facilitate transportation of viral samples at refrigerated and room temperatures prior to testing. Viral nucleic acids remain stable in MSS at room temperature for at least 14 days. By using MSS, infection hazard is reduced during transport and laboratory processing whilst preserving nucleic acids for identification by PCR or other nucleic acid techniques. MSS has a shelf life of 2 years from manufacture. MSS transport tubes are also compatible and validated for use with automated laboratory platforms. MSS is available in the following products:- 𝗦𝗪𝟬𝟬𝟬𝟰-𝗠𝟬𝟰𝟯-𝟮 𝗠𝗦𝗦 𝗦𝘄𝗮𝗯 𝗞𝗶𝘁 This kit is designed for sample collection and transport of viral and bacterial specimens. It comprises a transport tube of MSS (2ml fill) with red swab-capture cap, and a sterile small viscose tipped polystyrene swab with 78mm break-point, all encapsulated in an easy-peel pouch. The swab may be used to collect samples from areas including (but not limited to) the skin, nose, throat, anus and vagina, though the swab is not suitable for nasopharyngeal sampling. MSS Swab Kits are supplied in boxes of 100 kits. 𝗕𝗠𝟭𝟲𝟳𝟳-𝗠𝟬𝟰𝟯-𝟮 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻 (𝗠𝗦𝗦) This is a tray pack of 50 red-capped MSS filled transport tubes with 2ml fill. Additional information is available from the product flyer and Instructions For Use documents linked below. MSS Flyer https://lnkd.in/eZjCRZPS Swab Kit Instructions for Use (IFU) https://lnkd.in/eB2pS3ip BM1677 Instructions for Use (IFU) https://lnkd.in/emiG4EBs To order please contact your E&O Account Manager, or email enquiries@eolabs.com. References: (1) https://lnkd.in/e8jYWZxe